Analysed NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS) News Sources
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
01-06-2026
yahoo.com
EXCLUSIVE: France Based NurExone Targets Mexico Wellness Market With Exosome Supply Agreement
24-06-2026
yahoo.com
Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico
24-06-2026
yahoo.com
Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors
28-07-2026
yahoo.com
NurExone Launches Bioprocess Optimization Initiative to Support Commercial and Clinical Readiness
30-07-2026
yahoo.com
NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership
12-08-2026
yahoo.com
NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model
14-08-2026
yahoo.com
NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
28-08-2026
yahoo.com
What is the current price of NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS)?
The current price of NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS) is $0.4379.
NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS) since the previous trading day is $0.0388.
NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS) since the previous trading day is 9.7219%.
What is the most recent average sentiment score for NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS)?
The most recent average sentiment score for NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS) is 64 out of 100.
What is the most recent average sentiment for NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS)?
The most recent sentiment for NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS) is .
SEC-8K** Filing Available For NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.